HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, H. Articles by Woo, S. L.C. Search for Related Content PubMed PubMed Citation Articles by Dong, H. Articles by Woo, S. L.C. Social Bookmarking                What's this?

Basal Insulin Gene Expression Significantly Improves Conventional Insulin Therapy in Type 1 Diabetic Rats

¹ Carl C. Icahn Institute for Gene Therapy and Molecular Medicine and
² Department of Pathology, Mount Sinai School of Medicine, New York, New York

Although a conventional insulin regimen for type 1 diabetes with twice-daily insulin injections is effective in preventing postprandial blood glucose excursions, this treatment is limited by its inadequate control of fasting hyperglycemia. Alternatively, sustained basal hepatic insulin gene expression has been shown to result in fasting normoglycemia in type 1 diabetic rats, although the treated animals still exhibited moderate postprandial hyperglycemia. To test the hypothesis that basal hepatic insulin production can be used as an auxiliary treatment to conventional insulin therapy for achieving better glycemic control, streptozotocin-induced diabetic rats were treated with twice-daily insulin injections, basal hepatic insulin production, or both in combination. Diabetic rats treated by conventional insulin therapy still suffered from fasting hyperglycemia, but when complemented with basal hepatic insulin production, near-normoglycemia under both fed and fasting conditions was achieved without fasting hypoglycemia. In addition, the combination-treated animals showed significantly enhanced glucose tolerance and markedly improved profiles in lipid metabolism. Furthermore, the combination treatment reduced the elevated fructosamine, glycated hemoglobin, and advanced glycation end products concentrations to normal. These results provide a proof of concept for basal hepatic insulin production as an adjuvant treatment to conventional insulin therapy in type 1 diabetes.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice J. Lipid Res., July 1, 2007; 48(7): 1476 - 1487. [Abstract] [Full Text] [PDF]

				S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1 Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E421 - E434. [Abstract] [Full Text] [PDF]

				S. Qu, J. Altomonte, G. Perdomo, J. He, Y. Fan, A. Kamagate, M. Meseck, and H. H. Dong Aberrant Forkhead Box O1 Function Is Associated with Impaired Hepatic Metabolism Endocrinology, December 1, 2006; 147(12): 5641 - 5652. [Abstract] [Full Text] [PDF]

				N. Zhang, A. Richter, J. Suriawinata, S. Harbaran, J. Altomonte, L. Cong, H. Zhang, K. Song, M. Meseck, J. Bromberg, et al. Elevated Vascular Endothelial Growth Factor Production in Islets Improves Islet Graft Vascularization Diabetes, April 1, 2004; 53(4): 963 - 970. [Abstract] [Full Text] [PDF]

				J. Altomonte, A. Richter, S. Harbaran, J. Suriawinata, J. Nakae, S. N. Thung, M. Meseck, D. Accili, and H. Dong Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E718 - E728. [Abstract] [Full Text] [PDF]